Gordon Campbell | Parliament TV | Parliament Today | News Video | Crime | Employers | Housing | Immigration | Legal | Local Govt. | Maori | Welfare | Unions | Youth | Search


Ombudsman criticises Pharmac's approach to rare diseases

Ombudsman criticises Pharmac's approach to rare diseases

NZORD - the New Zealand Organisation for Rare Disorders

The Ombudsman has criticised a Pharmac decision from September 2012 on an exceptional circumstances application for a specialised medicine to treat Freda Evans who has Pompe disease. He has suggested Pharmac consider any further comments that Ms Evans wishes to make and give further specific consideration to items they have glossed over in their decision.

In the opinion released to the patient on 31 May 2013 and published 12 July 2013 Ombudsman Dr David McGee, who has since retired, raised a number of concerns about Pharmac’s policies and procedures. Specifically in the opinion:

He mentioned Pharmac’s documentation describing the decision criteria was “unduly complicated”.
He noted that Pharmac has a general discretion to consider applications despite the tight eligibility criteria in the Named Patient Pharmaceutical Assessment (NPPA) policy, but noted that the information on the policy did not explain this.
Dr McGee was concerned that Pharmac’s NPPA policy does not record the decision criteria to be used under that policy. He also considered the decision criteria under the NPPA policy ought to be clearly differentiated from those under the Pharmaceutical Schedule.
He was concerned that Pharmac didn’t specifically consider the patient’s suggestion for a trial period of the medicine. The Ombudsman said they should revisit this and consider any further comments on this suggestion the patient wishes to make.
He noted the lack of evidence in regard to rare diseases and treatments inevitably puts their assessment at a potential disadvantage.
Dr McGee specifically noted that the principle of states not abandoning their citizens is of obvious relevance where there is no known alternative method of treatment.
He noted a contestable legal argument about whether Pharmac appropriately excludes social and ethical factors from their consideration, though he said it was not his role to make a definitive decision on that legal dispute.
He considered that Pharmac should allow submissions to be made by Ms Evans and her supporters about questions of fairness, equity and community values, and consider these alongside submissions made by her clinician when the application is reconsidered.

· He identified “matters of high policy to be addressed by the Government and Parliament”.

Ms Evans’ complaint to the Ombudsman has been supported by the New Zealand Organisation for Rare disorders (NZORD), Lysosomal Diseases New Zealand (LDNZ), and the Muscular Dystrophy Association of New Zealand (MDANZ). “Our groups are delighted that our concerns have been heard in the system and responses provided that recognise the weakness of individuals against the enormous power of the bureaucracy,” said John Forman, NZORD’s executive director.

The groups have been seeking better accountability and governance oversight of Pharmac for many years. “We were frustrated that approaches to Ministers, the Health select committee, and other officials over the past two years since the development of the NPPA policy, had not resulted in any external scrutiny of Pharmac or response to our concerns,”, says Forman. “At last we have found a part of the system willing to investigate Pharmac and hold them to account, and Pharmac has been found seriously wanting.”

The Ombudsman’s report includes criticism of aspects of the relationship between Pharmac and District Health Boards, and concern was expressed by Dr McGee at Pharmac’s apparent power to bind DHB’s medicine purchasing decisions through a provision it has put in the schedule. Dr McGee said, “I have seen no statutory authority which allows Pharmac to give directions to DHBs, whether through the schedule or otherwise.”

Forman concluded by saying that the report vindicates many years of detailed work the groups have invested in scrutinising Pharmac’s operations. “Pharmac should be commended for the significant achievements it has made with a Pharmaceutical Schedule that provide good savings and good pharmaceutical outcomes for a great number of New Zealanders. But it is time for Pharmac to acknowledge that a strict health economics focus without a moral compass is abandoning patients at the margins. We hope that this opinion will cause Pharmac, government, Ministers, the Health select committee and other officials, to respond with serious scrutiny and review of Pharmac’s policies regarding specialised medicines for rare diseases.”

NZORD will assist with a further application for funding of the treatment (Myozyme) that Ms Evans needs, as soon as discussions with clinicians and other advisors are completed.


© Scoop Media

Parliament Headlines | Politics Headlines | Regional Headlines

Gordon Campbell: On Abortion Law Reform (And The US Electoral College)

Abortion is such a polarising issue that politicians commonly avoid it like the plague. Co-incidentally though, New Zealand and New South Wales are both trying to reform their abortion laws right now, at exactly the same time – and in our case, that reform is happening for the first time in 42 years.
This week at Parliament, a special select committee began taking public submissions on the legislation being proposed. More>>


Climate Change: Adaptation And Risk Assessment Framework Released

“We are already experiencing the effects of a changing climate such as coastal inundation and increasingly frequent and severe droughts, floods, fires and storms. This framework is an acknowledgement that we must start adapting”, James Shaw said today. More>>


Ihumātao: Mana Whenua Reach Decision On Land

Māori King Tūheitia says mana whenua have finally reached consensus over what to do with Ihumātao - they want it back. More>>


PM To Japan, New York: Ardern To Meet Trump During UN Trip

“I’m looking forward to discussing a wide range of international and regional issues with President Trump, including our cooperation in the Pacific and the trade relationship between our countries." More>>

PM's Post-Cab: "A Way Forward"

At Monday's post-cabinet press conference, Prime Minister Jacinda Ardern announced a number of actions in response to the Labour Party's mishandling of sexual assault complaints. More>>


Gordon Campbell: On Allegations Of Left Wing Media Bias

“Left wing bias” accusations date back at least to the mid 1990s... The charge of left wing bias was ridiculous then, and is ridiculous now. More>>

Next Wave Of Reforms: Gun Registration And Licensing Changes Announced

“The Bill includes a register to track firearms and new offences and penalties that can be applied extraterritorially for illegal manufacture, trafficking, and for falsifying, removing, or altering markings – which are a new requirement under the Firearms Protocol.” More>>


Gordon Campbell: On Labour’s Mishandling Of The Alleged Sexual Assault

The focus of Labour’s alleged sexual assault scandal has now shifted from the party organisation to the Beehive... This is now a crisis of Beehive management and response, not something occurring at a distance within the party organisation. More>>


'History Rectified': Rua Kēnana To Be Pardoned

An official pardon for Tūhoe prophet and leader Rua Kēnana is one step closer after the Te Pire kia Unuhia te Hara kai Runga i a Rua Kēnana: Rua Kēnana Pardon Bill was read in Parliament for the first time today. More>>





InfoPages News Channels